MedTrace Logo

Oral Valganciclovir Versus Valacyclovir

NCT00562770 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2012-07-31

No results posted yet for this study

Summary

To determine if the rate of cytomegalovirus reactivation during treatment with alemtuzumab (Campath) is reduced by the use of valganciclovir prophylaxis.

Conditions

Interventions

DRUG

Valganciclovir

900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.

DRUG

Valacyclovir

500 mg po QD during therapy and for 2 months post alemtuzumab initiation.

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Susan O'Brien, M.D. · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00562770 on ClinicalTrials.gov